Corporate presentation
Logotype for Definium Therapeutics Inc

Definium Therapeutics (DFTX) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Definium Therapeutics Inc

Corporate presentation summary

13 Nov, 2026

DT120 clinical results

  • Panorama met all primary and key secondary endpoints; 100 μg improved HAM-A vs. placebo by 5.1 points at week 12 (p<0.0001).

  • Voyage improved HAM-A vs. placebo by 5.4 points at week 12 and 7.7 points at week 1 (both p<0.0001).

  • Emerge improved MADRS vs. placebo by 8.1 points at week 6 and 7.3 points at week 12 (both p<0.0001).

  • Across pivotal readouts, DT120 100 μg was generally well tolerated, with no suicidality signal reported; mean time to EOSC clearance was 5.8–6.4 hours across studies.

  • Interim extension data through week 28 showed further HAM-A or MADRS improvement with additional open-label treatments in Panorama, Voyage and Emerge.

Development and regulatory plans

  • Ascend, a Phase 3 MDD study with target n=165, has a 2027 topline readout; Haven, a Phase 3 PTSD study with target n=200, is planned to initiate in 2027.

  • A pre-NDA meeting for DT120 is anticipated in 4Q 2026, with NDA filing targeted for 1H 2027; regulatory filing strategy for GAD and MDD is to be discussed at the meeting.

  • DT120 has FDA Breakthrough Therapy Designation in GAD and MDD; the presentation cites a statistically significant Phase 2b dose response and alignment with FDA guidance.

Commercial opportunity

  • The U.S. market framework identifies 50M adults with GAD or MDD, including 26M diagnosed, 13M prescription-treated and 4.2M failing 2+ prescriptions.

  • Market research found 58% of surveyed HCPs had positive views of DT120; awareness rose from 27% to 64% from 2024 to 2026, and 51% of high-priority HCPs said they would prescribe and administer it.

  • A modeled opportunity of $5B gross revenue assumes 2 patients per clinic per month across ~4,000 interventional psychiatry clinics and midpoint surrogate pricing based on Spravato; DT120 pricing is not established.

  • The proposed commercial model connects patients, providers and care sites through education, access, reimbursement, referral, site-readiness and treatment-day support.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Definium Therapeutics